How India Exports Teicoplanin to the World

As of March 2026, the FDA's Orange Book does not list any approved Abbreviated New Drug Applications (ANDAs) for teicoplanin, indicating the absence of generic versions in the U.S. market. In May 2018, the FDA granted orphan drug designation to Neupharma S.r.l. for teicoplanin for the treatment of Staphylococcus aureus lung infections in patients with cystic fibrosis. However, this designation does not equate to marketing approval. The lack of approved ANDAs suggests that Indian exporters may face challenges entering the U.S. market, potentially due to regulatory hurdles or limited market demand.

In the European Union, teicoplanin is marketed under the brand name Targocid by Sanofi-Aventis. In May 2013, the European Medicines Agency (EMA) completed a review of Targocid, leading to harmonized prescribing information across EU member states. Additionally, in August 2017, the EMA granted orphan designation to Neupharma S.r.l. for teicoplanin for the treatment of cystic fibrosis. This designation aims to encourage the development of medicines for rare diseases. Compliance with EU Good Manufacturing Practice (GMP) standards is mandatory for manufacturers exporting to the EU and UK markets.

Teicoplanin is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its importance in treating serious bacterial infections. The antibiotic is recognized in major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring standardized quality and efficacy across different regions.

In India, teicoplanin is classified under Schedule H of the Drugs and Cosmetics Rules, 1945, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) has not set a ceiling price for teicoplanin, allowing market-driven pricing. For exports, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC) to ensure compliance with national regulations and to monitor the export of critical pharmaceuticals.

Teicoplanin's primary patents have expired, leading to increased generic competition globally. This competitive landscape is reflected in India's export market, where 60 active exporters have engaged in teicoplanin shipments between 2022 and 2026.

In August 2022, the EMA published a list of nationally authorized medicinal products containing teicoplanin, following a periodic safety update report (PSUR) single assessment. This assessment led to variations in marketing authorizations to enhance safety information. In January 2021, the EMA's Committee for Medicinal Products for Human Use (CHMP) concluded a PSUR single assessment for teicoplanin, resulting in updated product information to reflect new safety data. These regulatory activities highlight the ongoing monitoring and updating of teicoplanin's safety profile within the EU.

Overall, while teicoplanin maintains a significant presence in global markets, particularly in the EU and select countries, its absence in the U.S. market and the competitive export environment from India underscore the importance of strategic regulatory navigation and market analysis for stakeholders.

India's pharmaceutical industry, including the production of Teicoplanin, heavily relies on Key Starting Materials (KSMs) sourced from China. According to the U.S. Pharmacopeia, 41% of KSMs used in U.S.-approved Active Pharmaceutical Ingredients (APIs) are solely sourced from China, while 16% come exclusively from India. This dependency poses significant risks, as any disruption in the supply of these critical materials can halt API production, leading to shortages of essential medications.

Recent geopolitical tensions have exacerbated these vulnerabilities. In February 2026, the closure of the Strait of Hormuz due to military conflicts disrupted the supply of raw materials to Asia's petrochemical industry, affecting the availability of essential chemicals for pharmaceutical manufacturing. Such disruptions underscore the fragility of supply chains dependent on concentrated sources for critical inputs.

Our proprietary trade data indicates a high supplier concentration in Teicoplanin exports from India. The top five exporters account for 90.3% of the total export value, with GUFIC BIOSCIENCES LIMITED alone contributing 71.8%. This concentration heightens the risk of supply disruptions, as issues affecting a single supplier can have disproportionate impacts on the global availability of Teicoplanin.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme aimed at boosting domestic manufacturing of critical APIs and reducing reliance on imports. In October 2024, two greenfield plants were inaugurated under this scheme to produce essential molecules like Penicillin G and Clavulanic Acid, marking a significant step toward self-sufficiency. However, the effectiveness of these initiatives in diversifying the supplier base for Teicoplanin remains to be seen.

The pharmaceutical supply chain is susceptible to geopolitical tensions and shipping disruptions. The closure of the Strait of Hormuz in February 2026 due to military conflicts has significantly impacted global supply chains, including the pharmaceutical sector. This disruption has led to delays and increased costs in the transportation of essential goods, including APIs and finished pharmaceutical products.

Additionally, tensions in the Red Sea and the Strait of Hormuz have further complicated shipping routes, leading to rerouting and extended transit times. Such disruptions can result in shortages and price increases for pharmaceuticals, as supply chains are forced to adapt to new logistical challenges.

• Diversify Supplier Base: Encourage the development of alternative suppliers for Teicoplanin and its KSMs to reduce dependency on a limited number of sources.

• Enhance Domestic Production: Invest in domestic manufacturing capabilities for critical APIs and KSMs to mitigate risks associated with import reliance.

• Strengthen Supply Chain Monitoring: Implement robust monitoring systems to detect early signs of supply chain disruptions and enable proactive responses.

• Develop Strategic Reserves: Establish reserves of essential APIs and KSMs to buffer against short-term supply interruptions.

• Foster International Collaboration: Engage in international partnerships to share information and resources, enhancing global supply chain resilience.

RISK_LEVEL: HIGH